Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T18:52:23.958Z.
Calculation as of: 2026-10-06T18:52:23.958Z.
Quote observation: 2026-10-06T18:49:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cbfdb9b702203632c67f1d3ce56f9042d1c779579fe07ac28526a5c99bc9a0a
EARNINGS YIELD
N/A
Market Cap
$443.12M
Earnings Yield
N/A
TTM Avg
1.29%
3Y Avg
1.29%
5Y Avg
1.29%
Market Cap
$437.49M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$437.47M
Earnings Yield
2.49%
TTM Avg
1.91%
3Y Avg
1.91%
5Y Avg
1.91%
Market Cap
$447.77M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$448.87M
Earnings Yield
N/A
TTM Avg
49.38%
3Y Avg
49.38%
5Y Avg
49.38%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $442.54M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $443.12M | N/A | 1.29% | 1.29% | 1.29% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $437.49M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $437.47M | 2.49% | 1.91% | 1.91% | 1.91% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $447.77M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $448.87M | N/A | 49.38% | 49.38% | 49.38% |
| Editas Medicine, Inc. (EDIT)vs › | $430.46M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $455.92M | 1.25% | 3.15% | 4.59% | 4.10% |
| NeoGenomics, Inc. (NEO)vs › | $428.85M | N/A | 4.67% | 2.17% | 1.96% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $427.50M | N/A | 0.52% | 0.52% | 0.52% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
